Recombinant Alpha-1 Antitrypsin–Fc Fusion Protein INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency: A Phase 1 Study

20248 citationsJournal Articlediamond Open Access

Authors

Mark Brantly · University of Florida

Brooks Kuhn · University of California, Davis

Humam Farah · Hannibal–LaGrange University

Ravi Mahadeva · University of Cambridge

Alexandra Cole · University of Florida

Catherina L. Chang · Waikato Hospital

Cynthia D. Brown ·

Abstract

The favorable safety profile and ability to maintain serum fAAT levels >21µM with extended-interval dosing, support a phase 2 trial evaluating Q3W and Q4W dosing of INBRX-101.

Topics & Keywords

Protease and Inhibitor Mechanisms Peptidase Inhibition and Analysis Blood Coagulation and Thrombosis Mechanisms

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation

Volume 11, Issue 3, pp. 282-292

DOI: 10.15326/jcopdf.2023.0469

Field-Weighted Citation Impact: 2.26